Orthocell (ASX:OCC) received a license from the Hong Kong Department of Health's Medical Device Division for its nerve collagen wrap product Remplir, according to a Monday Australian bourse filing.
The license allowing the company to sell the product in Hong Kong was originally expected to be granted in the fourth quarter.
The company intends to appoint a local on-the-ground specialist distributor to drive sales in Hong Kong, per the filing.
Orthocell's shares added over 3% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.